Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Tumor evolution is a primary cause of therapeutic failure and disease relapse in cancer treatment.
• Exposure-response (E-R) relationships are critical for determining effective drug doses.
• Current oncology drug development may not adequately address tumor evolution's impact on E-R relationships.

Purpose of the Study:

• To highlight the significance of tumor evolution in oncology drug development.
• To propose integrating tumor evolution dynamics into clinical development strategies.
• To enhance the selection of optimal doses for novel cancer therapeutics.

Main Methods:

• Review of existing literature on tumor evolution and drug response.
• Analysis of the impact of tumor heterogeneity on E-R modeling.
• Conceptual framework development for incorporating evolutionary principles into dose selection.

Main Results:

• Tumor evolution significantly alters drug exposure-response dynamics.
• Failure to account for tumor evolution can lead to suboptimal dosing and therapeutic failure.
• Early consideration of evolutionary trajectories can improve treatment efficacy.

Conclusions:

• Emphasizing tumor evolution in clinical development is crucial for optimizing oncology drug doses.
• This approach is particularly relevant for molecularly targeted therapies and immunotherapies.
• Project Optimus advocates for a paradigm shift in dose selection to combat resistance and relapse.